Cargando…
578. INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
BACKGROUND: Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with increased transmissibility, disease severity, and resistance to neutralization by current vaccines under emergency use authorization (EUA). Here we assessed cross-immune responses of INO-4800...
Autores principales: | Andrade, Viviane M, Christensen-Quick, Aaron, Agnes, Joseph, Tur, Jared, Reed, Charles C, Kalia, Richa, Marrero, Idania, Elwood, Dustin, Schultheis, Katherine, Purwar, Mansi, Reuschel, Emma, McMullan, Trevor, Pezzoli, Patrick, Kraynyak, Kimberly A, Sylvester, Albert, Mammen Jr., Mammen P, Tebas, Pablo, Kim, J Joseph, Weiner, David, Smith, Trevor R F, Ramos, Stephanie, Humeau, Laurent, Boyer, Jean, Broderick, Kate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644766/ http://dx.doi.org/10.1093/ofid/ofab466.776 |
Ejemplares similares
-
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
por: Andrade, Viviane M., et al.
Publicado: (2021) -
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
por: Tebas, Pablo, et al.
Publicado: (2021) -
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
por: Tebas, Pablo, et al.
Publicado: (2020) -
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
por: Walters, Jewell N., et al.
Publicado: (2022) -
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
por: Vonderheide, Robert H, et al.
Publicado: (2021)